Dept of Molecular Medicine International Speaker Series invites Dr. Robert Zweigerdt

Seminar: Upscaling human pluripotent stem cell culture and cardiac differentiation in suspension

Dept of Molecular Medicine International Speaker Series

Thursday Nov 26, 2015

1200-1330 AUD 13, Domus Medica, IMB

 

Dr Robert Zweigerdt

Leibniz Research Laboratories for Biotechnology and Artificial Organs

Hannover Medical School, Germany

 

Robert Zweigerdt studied Biology at the “Braunschweig University of Technology” (Germany) and was conducting research on early skeletal muscle development and transcriptional gene regulation in mice and in embryonic stem cells (ESC) during his PhD supervised by Hans Henning Arnold and Thomas Braun (current director of the Max Planck Institute on Heart and Lung Research in Bad Nauheim, Germany)

Moving to the Biotechnology Company “Cardion AG”, Zweigerdt collaborated with Jürgen Lehman (University Bielefeld, Germany), a pioneer in bioreactor development, and Loren Field (Indiana University School of Medicine, Indianapolis, US), a world-renowned researcher in heart muscle regeneration, to develop a novel process for the large scale production of pure, mouse ESC-derived cardiomyocytes.

In 2005, Zweigerdt became project manager at the Singapore-based Biotechnology Company “ES Cell International Pte Ltd” led by Dr. Alan Colman. Zweigerdt was responsible for developing a program aiming at the clinical translation of human ESC-derived cardiomyocytes and was involved in the characterization of the worlds’ first clinical-grade human ESC lines. In 2007 he was appointed Principal Investigator at the “A*Star Institute of Medical Biology” (IMB) in Singapore, continuing basic and applied research on human ESCs.

Since 2009 Zweigerdt has been PI at the “Leibniz Research Laboratories for Biotechnology and Artificial Organs” (LEBAO) at Hannover Medical School (MHH), Germany. In close collaboration with Ulrich Martin, he is developing processes for the production, molecular characterization and application of human induced pluripotent stem cells (hiPSCs) at clinical and industrial scales. Together with the group of Axel Haverich, head of the Department of Cardiac, Thoracic, Transplantation and Vascular Surgery (HTTG), Zweigerdt’s group is working on cell-based heart repair in pre-clinical animal models. Collaborative work within the “REBIRTH” cluster of excellence and in the European consortium “StemBANCC” aims at utilizing hiPSC-derived progeny for tissue engineering, in vitro disease modeling and pharmaceutical screening.